{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:40:29Z","timestamp":1783345229275,"version":"3.54.6"},"reference-count":50,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2008,6,10]],"date-time":"2008-06-10T00:00:00Z","timestamp":1213056000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2008,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Trifunctional bispecific antibodies can efficiently mediate tumor cell killing by redirecting T cells and immune accessory cells to the tumor cell. Here, we describe the new trifunctional antibody, Bi20 (FBTA05, anti\u2010CD20 \u00d7 anti\u2010CD3), that connects B cells and T cells <jats:italic>via<\/jats:italic> its variable regions and recruits Fc\u03b3RI<jats:sup>+<\/jats:sup> accessory immune cells <jats:italic>via<\/jats:italic> its Fc region. Bi20 mediated efficient and specific lysis of B\u2010cell lines and of B cells with low CD20 expression levels that were derived from CLL patients. Remarkably, T\u2010cell activation and tumor cell killing occurred in an entirely autologous setting without additional effector cells in 5 of 8 samples. In comparison, rituximab, a chimeric monoclonal CD20 antibody, demonstrated a significantly lower B\u2010cell eradication rate. Additionally, Bi20, but not rituximab, upregulated the activation markers CD25 and CD69 on both CD4<jats:sup>+<\/jats:sup> and CD8<jats:sup>+<\/jats:sup> T cells in the presence of accessory immune cells. CD14<jats:sup>+<\/jats:sup> accessory cells and the monocyte cell line THP\u20101 were activated <jats:italic>via<\/jats:italic> binding of the Fc region of Bi20, given that T cells were simultaneously engaged by the antibody. Bi20 induced a strong Th1 cytokine pattern characterized by high IFN\u2010\u03b3 and very low IL\u20104 secretion. In conclusion, Bi20 may offer new immunotherapeutic options for the treatment of B\u2010cell lymphomas. \u00a9 2008 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ijc.23626","type":"journal-article","created":{"date-parts":[[2008,6,10]],"date-time":"2008-06-10T21:17:58Z","timestamp":1213132678000},"page":"1181-1189","source":"Crossref","is-referenced-by-count":62,"title":["Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti\u2010CD20 \u00d7 anti\u2010CD3), mediates efficient killing of B\u2010cell lymphoma cells even with very low CD20 expression levels"],"prefix":"10.1002","volume":"123","author":[{"given":"Michael","family":"Stanglmaier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot","family":"Faltin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ruf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Bodenhausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Schr\u00f6der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horst","family":"Lindhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,6,10]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19950101)75:1 <370::AID-CNCR2820751319>3.0.CO;2-Q"},{"key":"e_1_2_6_3_2","volume-title":"SEER Cancer Statistics Review 1975\u20132003","author":"Ries LAG","year":"2006"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.6.8.1175"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2006.01.024"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.crvi.2005.12.006"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206939"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0268-960X(03)00039-0"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm736"},{"key":"e_1_2_6_10_2","first-page":"413","article-title":"Bispecific antibodies for polyclonal T\u2010cell engagement","volume":"5","author":"Baeuerle PA","year":"2003","journal-title":"Curr Opin Mol Ther"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1042\/BST0300507"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0215(200002)9999:9999<::AID-IJC1068>3.0.CO;2-D"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0215(200002)9999:9999<::AID-IJC1069>3.0.CO;2-A"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199509112195"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1237"},{"key":"e_1_2_6_16_2","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.4049\/jimmunol.163.3.1246","article-title":"Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing","volume":"163","author":"Zeidler R","year":"1999","journal-title":"J Immunol"},{"key":"e_1_2_6_17_2","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1182\/blood.V88.12.4651.bloodjournal88124651","article-title":"Bispecific antibodies target operationally tumor\u2010specific antigens in two leukemia relapse models","volume":"88","author":"Lindhofer H","year":"1996","journal-title":"Blood"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.8.2526"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21165"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/002215540104900711"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2436"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(94)90276-3"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002510050412"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI110005"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1309\/FNGCYEMJE3MAE5L2"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V63.6.1424.1424"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.5.1390.1390"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.155.1.219"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.11630"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.2.888"},{"key":"e_1_2_6_31_2","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","article-title":"Cytokine\u2010release syndrome in patients with B\u2010cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti\u2010CD20 monoclonal antibody (rituximab. IDEC\u2010C2B8)","volume":"94","author":"Winkler U","year":"1999","journal-title":"Blood"},{"key":"e_1_2_6_32_2","first-page":"27","article-title":"Impairments in immune cell function in B cell chronic lymphocytic leukemia","volume":"25","author":"Bartik MM","year":"1998","journal-title":"Semin Oncol"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2005.1.321"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199509049758"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1089\/scd.1.1995.4.433"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1309\/438N-E0FH-A5PR-XCAC"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.30155"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1707"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3835(01)00758-3"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19980831)77:5<763::AID-IJC16>3.0.CO;2-2"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0093-7754(03)00239-2"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1999.tb01725.x"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19990301)80:5<715::AID-IJC15>3.0.CO;2-P"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002620050432"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2004.00208.x"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-005-0675-4"},{"key":"e_1_2_6_47_2","first-page":"494","article-title":"Zeta chain and CD28 are poorly expressed on T lymphocytes from chronic lymphocytic leukemia","volume":"10","author":"Rossi E","year":"1996","journal-title":"Leukemia"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10557"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402890"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.1.137"},{"key":"e_1_2_6_51_2","first-page":"102a","article-title":"Adoptive immunotherapy of B\u2010cell malignancies with a trifunctinal, bispecific antibody (anti\u2010CD3 \u00d7 anti\u2010CD20) and allogeneic donor lymphocyte transfusion","volume":"91","author":"Buhmann R","year":"2006","journal-title":"Haematologica"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.23626","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.23626","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T07:04:20Z","timestamp":1697526260000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.23626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6,10]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["10.1002\/ijc.23626"],"URL":"https:\/\/doi.org\/10.1002\/ijc.23626","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6,10]]}}}